A number of Indian-owned generic pharmaceutical companies have been caught up in a sweeping US anti-trust investigation into price-fixing, bid-rigging and other anticompetitive behavior, amid mounting public anger over soaring drug bills.
The probe has further increased the pressure on the Indian industry, which is already feeling the strain from US regulatory
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?